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Undaria pinnatifida is a species of brown seaweed known to contain rich amounts of
fucoidan, a sulfated polysaccharide known to possess various biological activities. We iso-
lated crude fucoidan (F0) from the sporophylls of U. pinnatifida grown in the Marlborough
Sounds, New Zealand. Sulfate content, uronic acid content, and molecular weight of F0
were 15.02, 1.24, and >150 kDa, respectively. F0 was fractionated to yield three further
fractions: F1, F2, and F3. Cytotoxicity of two major fractions was determined by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.The algal fucoidans
specifically suppressed the proliferation of three cancer cell lines with less cytotoxicity
against the normal cells. Selective cytotoxicity could relate to the distinctive structures
of each fucoidan fraction. Results from this study provide evidence that fucoidan, espe-
cially from U. pinnatifida grown in New Zealand, possesses great potential to be used as
a functional food to reduce cancer risk or supplement cancer treatment.
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INTRODUCTION
Fucoidan is a group of sulfated heteropolysaccharide commonly
found in brown seaweeds (1). They are composed primarily of
l-fucose residues, and sulfate groups with smaller amounts of
d-galactose, d-mannose, d-xylose, d-glucose, uronic acids, and
protein (2). Numerous fucoidan types may coexist in the sporo-
phyll of the same algae and their composition varies between
species of brown seaweed (3). Since its first isolation from brown
seaweed in 1913 (4), fucoidan has been extensively studied. Due
to the popularity and increase in demand of pharmaceutical drugs
derived from natural sources, it was not until the last decade or
so have researchers focused more on the polysaccharides’ broad
range of physiological and biological activities (5, 6, 7). These
include beneficial cytotoxicity (1), anti-inflammatory (8), antivi-
ral (9), antioxidant (10), and anticoagulant activities (1). As a
result, fucoidans have great potential use in the production of new
therapeutic agents in the diagnosis and treatment of human dis-
eases. Consequently, research in this area and their cytotoxicity
was investigated. Previous studies have also showed that these bio-
logical activities were thought to be influenced by their degree of
sulfation (11), molecular mass (12), as well as the fucose:sulfate
molar ratio (13).
Cancer is a serious disease with complex pathological pathways
in the human body. The implementation of natural anticancer
agents has been recognized as a possible alternative to conventional
chemotherapeutic agents that are associated with minimal sur-
vival rates and unpleasant side effects (14). Fucoidan was reported
to suppress the growth of cancer cells in vivo, and enhances
the immune system to subdue the development of tumors (15).
Fucoidan was reported to induce a reduction in some types of
human cancer cell lines in a dose-dependent manner (16, 17),
and clinical trials of fucoidan ingested in human subjects had
given promising results (18). However, more research is required
in order to promote the use of fucoidan for potential chemothera-
peutic treatments. Sulfate content and molecular weight (Mw) of
fucoidan polymers have been reported to have a direct relationship
to fucoidans’ cytotoxicity and because fucoidan is a polymer mix-
ture, fucoidans extracted from different seaweed or different loca-
tions have different bioactivity (19). However, cytotoxicity of lower
and higher Mw fucoidans have not been investigated (11, 19).
Undaria pinnatifida is a brown seaweed native to Japan, China,
and Korea (20) where it is also commercially cultivated for food
production (21). It has now spread to over twelve countries includ-
ing France, Spain, Italy, Argentina, North and South America, Aus-
tralia, and New Zealand. Their ability to grow in a range of habitats
made U. pinnatifida an unwanted organism in New Zealand, and
was therefore illegal to harvest U. pinnatifida commercially (20).
Hence structural information on fucoidan from New Zealand U.
pinnatifida has not been reported. Few studies have been carried
out to investigate the anticancer activity of fucoidan extracted
from U. pinnatifida (11, 16, 19). In particular, knowledge on
the bioactivity of fucoidan from New Zealand brown seaweed
on human cancer cell lines was absent. Hence the present study
was undertaken to first characterize the chemical composition of
fucoidan from New Zealand U. pinnatifida. Crude fucoidan (F0)
was then purified using anion-exchange chromatography to yield
three fractions (F1, F2, and F3), and their cytotoxicity were inves-
tigated against MCF-7 (breast adenocarcinoma cell line), A-549
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(lung carcinoma cell line), WiDr (colon adenocarcinoma cell line),
Malme-3M (lung melanoma cell line), HEK-293 (human embry-
onic kidney cell line), LoVo (human colon adenocarcinoma cell
line), HUVEC (Human Umbilical Vein Endothelial Cell line), and
HDFb (Human Derma Fibroblast cell line) cells using the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)
cell proliferation assay in comparison with commercial fucoidan
(Sigma, USA). The relationship between cytotoxicity and chemical
composition was also examined and discussed.
MATERIALS AND METHODS
MATERIALS
Undaria pinnatifida was harvested from Port Underwood, New
Zealand in September 2011 from two selected mussel farms (farms
106 and 327). The two seaweed samples were independently pre-
pared for extraction. The sporophyll and blade were separated into
labeled bags and lyophilized (Christ LOC 1-M Alpha 2-4, Mar-
tin Christ, Osterode am Harz, Germany) in bulk within 48 h of
frozen storage. The dried sample was milled using a coffee grinder
(Breville CG2B), sieved (<0.6 mm) and then stored in PET con-
tainers at room temperature before analyses (22). All chemicals
and reagents were of analytical grade.
EXTRACTION OF FUCOIDAN
Crude fucoidan was extracted as described previously (13). Each
extraction was carried out using sporophylls from separate plants
harvested in September, 2011. Four replicate samples of dried
algal biomass (15 g) was treated at room temperature for 24 h
with a MeOH–CHCl3–water mixture (4:2:1) to remove lipids,
protein, and colored pigments. The treated algal biomass was
filtered through a Whatman’s filter paper (90 mm GF/D), then
washed with acetone and dried overnight at room temperature.
Treated algae (10 g) were mechanically stirred with 2% aque-
ous CaCl2 (100 mL) at 85°C for 5 h. The extract was centrifuged
at 18500 g (Eppendorf Centrifuge 5810R V3.1, Eppendorf AG,
Hamburg, Germany) and the supernatant was collected. A hexa-
decyltrimethylammonium bromide (cetavlon) solution (10%,
50 mL) was added to the extract and was left to precipitate at
4°C overnight. The precipitate was centrifuged at 18500 g, washed
with water and mechanically stirred with 60 mL ethanolic NaI
solution (20%) for 72 h. The precipitate was removed by centrifu-
gation, washed with ethanol and lyophilized (Christ LOC 1-M
Alpha 2-4, Martin Christ, Osterode am Harz, Germany) to give
crude fucoidan (23).
DETERMINATION OF SULFATE, URONIC ACID, AND PROTEIN CONTENT
Sulfate content was quantified using the BaCl2-gelatin method
using K2SO4 as the standard after hydrolyzing fucoidan (15 mg)
in 4 M HCl for 2 h at 100°C (24). Uronic acid and protein con-
tent of fucoidan were determined using the carbazole–sulfuric
acid–borate reaction using d-glucuronic acid as the standard (25),
and the Bradford assay using bovine serum albumin as the stan-
dard (26), respectively. Absorbance measurements were recorded
using an Ultrospec 2100 UV/visible spectrophotometer. Experi-
ments were performed in triplicates as three independent assays.
All yields were calculated from the dried weight of fucoidan and
converted to a percentage.
FRACTIONATION OF FUCOIDAN
Crude fucoidan was purified by fractionation using anion-
exchange chromatography. Crude fucoidan (2 g) was dissolved in
20 mL of Tris-HCl buffer (0.05 M, pH 7.4) and applied to a col-
umn (25 cm× 4 cm) of DEAE–Sephadex A-25 (Pharmacia Ltd.)
equilibrated with Tris-HCl buffer connected to a Bio-Rad 2110
fraction collector. The first fraction was eluted with deionized
water at a flow rate of 40 drops per tube, followed by NaCl elu-
tion at increasing concentrations (1 and 2 M) until the absence
of a positive reaction for the presence of sugars in the test tubes
when using the phenol–sulfuric acid method according to Dubois
et al. (27). Briefly, test tubes containing the eluted samples were
transferred (1 mL) into more robust glass test tubes (5 mL). Then
0.05 mL 80% phenol and 2.5 mL concentrated H2SO4 were added
to each test tube and mixed thoroughly. Test tubes were placed
on a rack and heated in a 35°C water bath for 20 min. The
absorbance was measured at 480 nm (Ultrospec 2100) for any
indication of sugars and uronic acids (27). Each carbohydrate-
positive fraction was pooled together, dialyzed for 72 h (MWCO
12–14,000) in deionized water with a water change daily and then
lyophilized.
DETERMINATION OF MONOSACCHARIDE COMPOSITION
Monosaccharides were analyzed by gas chromatography of their
alditol acetate derivatives (28). Fucoidan (10 mg) was hydrolyzed
in 0.5 mL of 2 M trifluoroacetic acid at 121°C in sealed glass
tubes flushed with nitrogen for 4 h. After cooling to room tem-
perature, 25µL of 20 mg/mL allose was added as an internal
reference. The hydrolyzate was filtered through a 0.2µm Phenex-
RC syringe filter into clean glass tubes and evaporated to dryness
with a gentle stream of filtered air. Milli-Q water (100µL) was
added to the dried hydrolyzates and incubated at 40°C for 90 min
after the addition of 20µL of 15 M ammonia and 1 mL of 0.5 M
sodium borohydride in dimethyl-sulfoxide (DMSO). After cool-
ing to room temperature, 1-methylimidazole (200µL) and acetic
anhydride (2 mL) was added to the mixture and incubated for a
further 10 min. Milli-Q water (5 mL) was added into each tube
to neutralize the excess acetic anhydride and allowed to cool to
room temperature. Alditol acetates were extracted by the addi-
tion of 1 mL dichloromethane (DCM), and the lower DCM phase
was transferred using a Pasteur pipette into a clean glass test tube.
This extraction was repeated once more. The combined DCM
extracts was washed with 4 mL Milli-Q water and the upper water
phase was discarded. The wash was repeated twice more. Alditol
acetates were analyzed by GC (GC-2010, Shimadzu) using a ZB-5
capillary column (30 mm× 0.25 mm) coupled to a flame ioniza-
tion detector. The detector temperature was held at 280°C while
the injector temperature was set at 240°C. Nitrogen was used as
the carrier gas at a flow rate of 1.5 mL/min and a split ratio of
10. The oven temperature was set at 38°C for 1 min, increased
to 200°C at 50°C/min, further increased to 210°C at 2°C/min,
and then held for 5 min at the final temperature. Sugar standards
used were: l(−)-fucose (Sigma, USA),d(+)-galactose (Serva, Ger-
many), d(+)-xylose (Sigma, USA), d(+)-mannose (Sigma, USA),
α-d(+)-glucose (Sigma, USA), and β-d-allose (Sigma, USA).
Preparations of sugar standards to their alditol acetate derivatives
were identical to that of crude fucoidan. Due to limited resources
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from farm 106, only U. pinnatifida from farm 327 was analyzed
for monosaccharide content.
DETERMINATION OF AVERAGE MOLECULAR WEIGHT
Average Mw of fucoidan from the sporophylls of U. pinnatifida
was determined by gel permeation chromatography (GPC) using
a Sephadex G-100 column (25 cm× 4 cm) equilibrated with phos-
phate buffer (Bio-Lab Ltd.) (10 mM, pH 7). Crude fucoidan, its
fractions (F1, F2, and F3), and commercial fucoidan (10 mg each)
were dissolved in 1 mL phosphate buffer and applied to the column
at a flow rate of 40 drops per tube. Presence of sugars was detected
using the phenol–sulfuric acid method (27). Dextrans (12, 25, 50,
80, 150 KDa) purchased from Sigma were used as standard Mw
markers. Blue Dextran 2000 (Pharmacia, Sweden) was used as a
void volume marker.
CELL REDUCING CAPACITY (CYTOTOXICITY) ASSAY
A-549 cells (lung carcinoma cell line, ATCC CCL-185™), WiDr
cells (colon adenocarcinoma cell line, ATCC CCL-218™), MCF-7
cells (breast adenocarcinoma cell line, ATCC HTB-22™), Malme-
3M cells (lung melanoma cell line, ATCC HTB-64™), HEK-293
cells (human embryonic kidney cell line, ATCC CRL-1573™),
HUVEC cells (human umbilical vein endothelial cell line, ATCC
PCS-100-010™), LoVo cells (human colon adenocarcinoma cell
line, ATCC CCL-229™), and HDFb cells (human derma fibrob-
last cell line, Invitrogen NZ Limited) were each cultured in 5 mL
of Roswell Park Memorial Institute 1640 (RPMI 1640) com-
plete medium (GIBCO, USA) supplemented with 1% Penicillin–
Streptomycin (Invitrogen, USA), 1% l-glutamine (Invitrogen,
USA) and 10% fetal bovine serum (Medica Pacifica, USA) at 37°C
in a 5% CO2 atmosphere.
The cytotoxicity/cell reducing capacity of crude fucoidan (F0)
and its fractions (F1 and F3) was determined using the MTT cell
proliferation assay (29). Each cell line (A-549, WiDr and MCF-7)
was sub-cultured (100µL) in 96-well plates at a density of 1× 105
cells per well and allowed to attach to the well bottom for 24 h
in 5% CO2 at 37°C. Different concentrations (0.2–1.0 mg mL−1)
of crude fucoidan (F0), its fractions (F1 and F3), and commer-
cial fucoidan (Fucus vesiculosus, Sigma, USA) were added into the
wells (100µL) and were incubated for a further 24 h. The super-
natant was removed and washed with 150µL of PBS (pH 7.2) and
removed again. The plates were re-incubated for 4 h after the addi-
tion of 30µL of MTT (5 mM,in phosphate buffered saline solution
at pH 7.2) reagent and a further 30 min after adding 150µL of
DMSO. Absorbance of each well was measured at 540 nm using
a FLUOstar Omega microplate reader (Alphatech, New Zealand).
Assays were performed after treatment of cells for 24, 48, and 72 h.
The data were used to calculate the cell viability percentage using
the equation below. The IC50 value was calculated using Prism 5
(GraphPad Software Inc., San Diego, CA, USA).
Cell Viability (%)
=
1−
(Abs of control− Abs of blank)
− (Abs of sample− Abs of blank)
(Abs of control− Abs of blank)
× 100
STATISTICAL ANALYSIS
Analysis of variance (ANOVA) was carried out using Minitab®
(Version 15) to test for differences between fucoidan fractions.
Results of all tests were considered significant if p< 0.05. Where
significant differences occurred, the Tukey’s Honest Significance
Difference (HSD) test was employed to examine where that effect
occurred.
RESULTS
CRUDE FUCOIDAN YIELD AND CHEMICAL COMPOSITION
Crude fucoidan was extracted from the sporophylls of New
Zealand U. pinnatifida by CaCl2 extraction. Yield of sporophyll-
derived fucoidan were 69.98± 0.99% and 57.28± 6.18% dry
weight from farms 327 and 106, respectively. Sporophyll-derived
fucoidan contained 7.9 times more fucoidan from site 327 than
U. pinnatifida harvested in the Kyoungbuk province, Korea while
site 106 was 6.5 times more although the extraction method
between the two studies was different (19). However, yields of
sporophyll-derived crude fucoidan from both sites were slightly
lower compared to 71.50% yield previously reported from Sar-
gassum wightii collected along the coast of Gulf of Mannar, India
(30). As shown in Table 1, crude fucoidan (F0) was shown to be
composed primarily of fucose (39.24%), xylose (28.85%), galac-
tose (26.48%), and sulfate (15.02%). The minor components
were made up of mannose (5.04%), glucose (0.95%), uronic acid
(1.24%), and protein (0.36%). A sample chromatogram of the
separate monosaccharides is shown in Figure 1.
FRACTIONATION OF CRUDE FUCOIDAN
Crude fucoidan (F0) was fractionated by DEAE–Sephadex A-25
to yield three fractions, F1, F2, and F3 (Figure 2). No polysac-
charide was detected when using 3 M NaCl elution. All fractions
contained fucose as the major sugar component followed by
galactose, with small amounts of mannose, xylose, and glucose
also present. However, the sugar composition varied among the
three fractions (Table 1). The fractions were not sulfated xylo-
galactofucans like crude fucoidan, but were made up of sulfated
galactofucans instead. The fraction eluted with a low NaCl con-
centration was higher in uronic acid and lower in sulfate content.
Conversely, the fraction that was eluted with high NaCl concentra-
tion was higher in sulfate content and lower in uronic acid. This
was similarly encountered with fucoidan from S. swartzii (31).
The content of fucose increased significantly (p< 0.001) from F0
to F3 (Table 1), followed by a significant decrease in xylose con-
tent (p< 0.001). No noticeable changes between fractions were
observed for galactose, mannose, and glucose. Protein content of
the different fractions was also similar between F0, F2, and F3, but
a significant decrease (p= 0.014) in protein content from F1 to F3
fractions indicated less protein contamination when using higher
NaCl elution.
MOLECULAR WEIGHT ESTIMATION OF FUCOIDAN BY GPC
The average Mw of crude fucoidan from the sporophylls of New
Zealand U. pinnatifida was estimated to be over 150 kDa by GPC,
after calibration with known standard Mw markers. The mass of
crude fucoidan from New Zealand U. pinnatifida was higher than
crude fucoidan from the sporophylls of the same species harvested
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Table 1 | Chemical composition of crude fucoidan (F0) from U. pinnatifida, its purified fractions (F1, F2, and F3) from farm 327 and commercial
fucoidan (Sigma).
Sample Uronic acid (%) Sulphate (%) Protein (%) Mw (kDa) Monosaccharide composition (%)
Fuc Gal Xyl Glc Man
F0 1.24c 15.02d 0.36b,c >150 39.24d 26.48b 28.85a 0.95b 5.04b
F1 4.34a 6.96e 0.86a 81 48.51c 37.86a 3.74b 2.91a 6.97a
F2 0.84c 22.78b 0.63b 22 53.21b,c 42.12a 1.15b 1.28b 2.24c
F 0.67c 25.19a 0.11c 27 59.71b 28.74b 1.58b 2.77a 7.19a
Sigma 3.14b 17.96c 0.41b,c 54 87.12a 5.69c 4.85b 0.94b 1.39c
a,b,c,d,eColumn wise values with different superscripts indicate significant differences at p<0.05 by one-way ANOVA followed by theTukey’s post hoc comparison test.
FIGURE 1 | Gas chromatogram of monosaccharide content of fucoidan obtained from U. pinnatifida as alditol acetate derivatives. (A) Fucitol
pentaacetate; (B) Xylitol pentaacetate; (C) Allitol hexaacetate; (D) Mannitol hexaacetate; (E) Galactitol hexaacetate; (F) Glucitol hexaacetate.
from Kijang, Korea that had a Mw of only 38 kDa (32). Conversely,
fucoidan extracted from the sporophylls of U. pinnatifida grown
in Wando, Korea had a much higher average Mw of 2100 kDa (6).
The large differences in Mw from the same species were proba-
bly attributed to the different fucoidan extraction techniques used
that may render fucoidan unstable when heating (33). Variation in
Mw of fucoidans from U. pinnatifida was also reported by Fitton
and Dragar (34). In this study, the Mw of fucoidan fractions eluted
with water, 1 and 2 M NaCl were 81, 22, and 27 kDa, respectively
(Table 1). The Mw of commercial fucoidan from F. vesiculosis
purchased from Sigma was estimated to be 54 kDa, which was
within the specified range obtained from the Sigma database of
20–200 kDa (35).
CELL REDUCING CAPACITY OF FUCOIDAN ON CANCER CELL LINES
Cell reducing capacity of crude (F0) and purified fucoidan frac-
tions (F1 and F3) toward A-549 (lung carcinoma), WiDr (colon
adenocarcinoma), MCF-7 (breast adenocarcinoma), Malme-3M
(lung melanoma), and LoVo (human colon adenocarcinoma) cell
lines were examined, and compared with commercial fucoidan
from Sigma. Each cell line was treated with different concentra-
tions of fucoidan (0.2–1.0 mg/mL) for 24, 48, and 72 h and assessed
for cell viability using the MTT cell proliferation assay. This assay
was based on the presence of mitochondrial dehydrogenase in
viable cells to react with the yellow MTT to form a dark blue–
purple formazan complex,which can be solubilized by the addition
of DMSO. The amount of viable cells left remaining is directly pro-
portional to the amount of formazan complex produced (36). The
cell reducing capacity of fucoidan, expressed as the percentage of
viable cells left remaining after fucoidan treatment on MCF-7, A-
549, WiDr, Malme-3M, and LoVo cell lines, is shown in Figure 3,
while the IC50 values (the half minimal inhibitory concentration
of a substance) are shown in Table 2. F2 was not included in the
cytotoxicity test since this was the smallest of the three purified
Frontiers in Nutrition | Nutrition and Food Science Technology July 2014 | Volume 1 | Article 9 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mak et al. Fucoidan of NZ Undaria pinnatifida
FIGURE 2 | Chromatogram of purified crude fucoidan extracts obtained
from U. pinnatifida separated on a DEAE–Sephadex A-25 column.
fractions and was difficult to obtain sufficient amounts required
for the MTT assay.
As shown in Figure 3, treatment of A-549 (A),MCF-7 (B),WiDr
(C), LoVo (G), and Malme-3M (H) cell lines with all fucoidan sam-
ples showed a dose-dependent and time-dependent relationship
at the concentrations (0.2–1.0 mg/mL) tested. The IC50 values of
crude fucoidan (F0) from this study indicated a higher cytotoxic-
ity than purified fractions (F1 and F3) and commercial fucoidan
against both the MCF-7 breast cancer cells and A-549 lung can-
cer cells after 72 h cultivation (Table 2). At concentrations from
0.2 to 1.0 mg/mL, F0 inhibited the development of cancer cells
in a strong dose-dependent relationship and had cell viabilities
that ranged from 52.1 to 0.4% against A-549 cells and 12.4–1.7%
against MCF-7 cells after 72 h incubation. Moreover, F1 and F3
purified fractions had lower IC50 values indicating higher cell
reducing capacity than commercial fucoidan when subjected to
A-549 cells, while commercial fucoidan showed less cell reducing
capacity than F0 and F3 when applied to MCF-7 cells. Conversely,
commercial fucoidan exhibited the strongest cell reducing capac-
ity against WiDr colon cancer cells than F0, F1, and F3 with IC50
values of 0.069, 0.121, and 0.072 mg/mL, respectively after 72 h
incubation. The fact that commercial fucoidan had stronger cell
reducing capacity than F0, F1, and F3 although its sulfate content is
lower than F3 could be explained by the low Mw and high uronic
acid content which both also increase the cell reducing capacity
potential of fucoidans (31).
Considerable variations in cell reducing capacity were encoun-
tered for both crude fucoidan and fucoidan fractions on different
cell lines. Commercial fucoidan showing much higher inhibitory
action on WiDr cells than on MCF-7, A-549, Malme-3M, and
LoVo cells (p< 0.001). Similarly, F1 and F3 fucoidan fractions had
lower IC50 values for WiDr cells that were associated with a higher
inhibitory action than the MCF-7 and A-549 cells. These results
reported for the first time that the WiDr colon cancer cells were
more susceptible to the inhibitory action of fucoidan compared to
the MCF-7 and A-549 cells. A previous study reported that com-
mercial fucoidan from F. vesiculosis (Sigma, USA) inhibited the
growth of HT-29 colon cancer cells (14), a derivative of the WiDr
colon cancer cells (37).
A trend was observed where crude fucoidan exhibited stronger
cell reducing capacity than its lower Mw fractions for MCF-7,
A-549, and WiDr cell lines. This finding was consistent with the
results from a previous study, which reported a stronger inhibitory
action of crude fucoidan from Utricularia aurea compared to its
purified fractions on KB nasopharynx cancer cells (38). Although
it has been suggested that fucoidans with a lower Mw and higher
sulfate content would provide stronger cell reducing capacity (1,
19), results from this study showed otherwise. This is due to the
fact that crude fucoidan in this study, which had the highest Mw
of over 150 kDa and a lower sulfate content than the purified frac-
tion F3 (Table 1) exhibited the highest cell reducing capacity. This
could be attributed to structural changes during the fractionation
process such as depolymerization or by other features in crude
fucoidan that may have cell reducing capacity effects (38) that
may include the high amount of xylose present in crude fucoidan.
Xylose has been used in the past as a component in the develop-
ment of anticancer drugs (39), and thus there is a reason to believe
that xylose content in crude fucoidan may play a vital role in the
cell reducing capacity of fucoidans.
CELL REDUCING CAPACITY OF FUCOIDAN ON NON-CANCER CELL LINES
Although the cell reducing capacity of fucoidan on certain cancer
cells is effective, fucoidan’s selectivity on whether or not to attack
non-cancer cells still remains unclear and the mechanisms of how
they inhibit tumor growth are still not entirely understood (7). To
be able to determine whether the fucoidans in this study had any
effect on non-cancer cell lines, assessment of the effects of fucoidan
on HUVEC, HDFb, and HEK-293 cell lines were measured using
the MTT assay. Cell reducing capacity effects of fucoidan on all
three non-cancer cell lines showed a dose-dependent manner, with
HUVEC being the most sensitive to crude fucoidan with a reduc-
tion of viable cells to 13.0% after 72 h incubation at a concentration
of 1 mg/mL crude fucoidan (Figure 3). A drastic reduction in cell
viability was encountered for commercial fucoidan from 78.1%
cell viability down to 41.7% upon increasing the concentration
from 0.2 to 0.6 mg/mL at 24 h incubation. A trend was also noted
that F3 had significantly weaker cell reduction rates than F0 and
F1 at 0.2–1.0 mg/mL dosage levels for 24 h (p< 0.001), but no
significant differences were observed between F0 and F1 at the
same concentrations and incubation period (p< 0.001). Fucoidan
also inhibited the growth of HEK-293 and HDFb cells in a dose-
dependent fashion. However the extent of inhibition, based on cell
viability (Figure 3), was smaller than with the HUVEC cells. The
treatment of HEK-293 cells with 1 mg/mL crude fucoidan for 72 h
incubation had a 63.7% cell reduction whereas at the same con-
centration of crude fucoidan and incubation period, HDFb cells
had a 79.8% cell reduction, both having a significantly lower cell
reduction rate than with WiDr (96.22%), MCF-7 (98.32%), and
A-549 (99.96%) cancer cells.
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FIGURE 3 | Cytotoxicity of crude fucoidan (F0), fractionated fucoidan
(F1 and F3) and commercial fucoidan (Sigma) against eight cancer or
non-cancer cell lines: (A) A-549; (B) MCF-7; (C) WiDr; (D) HDFb;
(E) HEK-293; (F) HUVEC; (G) LoVo; and (H) Malme-3M cells after 24,
48, and 72 h incubation. Results are the means of three independent
tests±SE.
DISCUSSION
This is the first study to investigate fucoidan’s composition and
cytotoxicity extracted from New Zealand U. pinnatifida. Since
fucoidan is a carbohydrate polymer mixture, fucoidans extracted
from different seaweed or from same species but growing at dif-
ferent locations have different bioactivity, including in vitro cell
reducing capacity in tumor cells (40). Hence, it is important
to study fucoidan extracted from U. pinnatifida grown in New
Zealand to identify whether it has any unique characteristics and
biological functions.
The sugar composition and sulfate content indicated that crude
fucoidan isolated from the sporophylls of U. pinnatifida from
New Zealand was made up of sulfated xylogalactofucans. Pro-
tein content of New Zealand fucoidan was much lower than in
other fucoidans reported (1, 12, 41). This indicated the effective-
ness of the extraction technique used in this study to eliminate
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Table 2 | Effect of crude fucoidan (F0), its fractions (F1 and F3) and commercial fucoidan (Sigma) toward MCF-7, A-549,WiDr, Malme-3M, LoVo,
HDFb, HUVEC, and HEK-293 cell lines at three different incubation times (24, 48, and 72 h).
Cell line Incubation period (h) Cell type F0b F1b F3b Sigmab
TUMORa
MCF-7 24 Breast adenocarcinoma 0.173 0.651 0.405 0.515
48 0.024 0.245 0.231 0.221
72 0.010 0.148 0.110 0.134
A-549 24 Lung carcinoma 0.869 1.018 0.453 0.869
48 0.278 0.675 0.315 0.744
72 0.147 0.372 0.242 0.582
WiDr 24 Colon adenocarcinoma 0.244 0.400 0.216 0.321
48 0.146 0.220 0.173 0.072
72 0.069 0.121 0.072 0.038
Malme-3M 24 Lung melanoma >50c >70c >140c >80c
48 >40c >40c >90c >60c
72 >30c >30c >60c >50c
LoVo 24 Colon adenocarcinoma 19.090 d d 1.548
48 1.358 2.044 7.596 0.264
72 0.394 1.051 2.210 0.121
NON-TUMORa
HDFb 24 Derma fibroblast >40c >30c >90c 18.132
48 18.397 18.436 >70c 12.845
72 13.532 14.542 >40c 9.745
HUVEC 24 Umbilical vein 24.828 26.246 >40c 26.053
48 10.108 11.604 24.794 7.142
72 7.339 6.672 12.854 5.722
HEK-293 24 Embryonic kidney 0.0605 0.057 0.091 >40c
48 0.046 0.030 0.056 28.520
72 0.022 0.019 0.046 9.523
aIC50 (mg/mL) was evaluated by the MTT assay, as reported in Section “Cell reducing capacity (cytotoxicity) assay.”
bResults are the mean of three independent experiments.
cValues are extrapolated.
dNot determined.
Results are expressed as IC50 (mg/mL).
protein contamination (41). Negatively charged sulfate and uronic
acid components of crude fucoidan were more or less lower than
fucoidan extracted from S. swartzii (31) and Laminaria japonica
(12). Fucose content in crude fucoidan was somewhat lower than
fucoidans extracted from U. pinnatifida in Korea (19, 21). How-
ever, using different fucoidan extraction methods, galactose and
xylose content of fucoidan from New Zealand U. pinnatifida were
much higher than Korean fucoidan indicating that monosaccha-
ride variations exist within the same species grown in different
countries. At present, no reports have reported about xylogalacto-
fucans being extracted from U. pinnatifida but there have been
reports for other species including L. angustata (42), Sphacelaria
indica (43), and Spatoglossum schroederi (44). Fucose content
from commercial fucoidan derived from F. vesiculosus was sig-
nificantly higher (p< 0.001) than our crude fucoidan. However,
xylose, galactose, and mannose content were significantly lower in
commercial fucoidan compared to crude fucoidan (Table 1). Vari-
ations in fucoidan yield and chemical composition was possibly
attributed to the difference in fucoidan extraction techniques, alga
harvest season, harvest location, degree of alga maturation, and
alga species (3, 32, 45).
A decrease in Mw was observed from F0 to F3 fucoidan fractions
as NaCl concentration increased. This change in Mw pattern was
also observed with fucoidan extracted from U. pinnatifida grown
in Peter the Great Bay, using a DEAE–Sephadex A-25 column (3).
The decrease in Mw of the fractions was assumed to be caused by
depolymerization of fucoidan during the fractionation process (9).
In the present work, purified fucoidan fractions from New Zealand
U. pinnatifida harvested in the Marlborough Sounds, New Zealand
was found to be sulfated galactofucans with high Mw. These results
also showed that crude fucoidan from New Zealand U. pinnatifida
were heterogeneous in terms of its sulfate content, uronic acid
content, and monosaccharide composition. This is supported by
previous studies that have also reported fucoidan from S. swartzii,
Pelvetia canaliculata, F. vesiculosus, S. muticum, and L. digitata as
being heterogeneous (31, 46).
The cytotoxicity findings in this study confirmed that crude
fucoidan had strong cell reducing capacity, as reported by other
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studies, using fucoidan from the sporophylls of U. pinnatifida (1,
16). The cell reducing capacity of crude fucoidan on MCF-7 cells
over 48 h was considerably higher than fucoidan polymers from
A. nodosum harvested from Ireland, which showed no significant
decrease in viable cell numbers over 48 h (47). Similarly, when
fucoidan purchased from the NPO Research Institute of Fucoidan,
Japan was tested, the number of MCF-7 cells after 48 h incuba-
tion increased from approximately 15× 104 to 18× 104 cells/well,
meaning there was no inhibition of MCF-7 cells. However, a sig-
nificant decrease in viable cell numbers was only achieved after
96 h incubation period (48). In this study, the degree of inhibition
of crude fucoidan on MCF-7 cells was much higher; with only
2.6% viable cells left remaining after 48 h. The results also showed
that fucoidan reacted differently to the cell type used, with A-
549 cells less sensitive to fucoidans, thereby having a higher IC50
value compared to MCF-7 and WiDr cells (Table 2). Fucoidan
from the sporophylls of U. pinnatifida from South Korea inhibited
the growth of A-549 cells from 85.1 to 62.4% at concentrations
from 0.2 to 1.0 mg/mL (19). The degree of A-549 inhibition was,
however, higher in this study, with 67.5–32.7% inhibition at con-
centrations from 0.2 to 1.0 mg/mL after 24 h incubation with crude
fucoidan. In addition, cell reducing capacity of crude fucoidan
from the sporophylls of Korean U. pinnatifida against A-549 cells
was much lower than crude fucoidan from this study when com-
parisons were made between the cell viability graphs obtained
from their study and ours (16). This confirmed that fucoidan poly-
mers from the same species may result in different cell proliferation
capacities that could be due to differences in structural properties
and cell type procedures (38).
The results also revealed that fucoidan inhibited dose-
dependently of LoVo and Malme-3M cells, although the level of
cell reducing capacity was much less than what was encountered
with A-549, WiDr, and MCF-7. All fucoidan fractions (F0, F1, and
F3) after incubation for 24 h showed significantly less inhibition
of LoVo cells when compared to A-549, MCF-7, and WiDr cells
at the same incubation period (p< 0.001). Commercial fucoidan
showed the strongest effect of suppression for LoVo cells at 24,
48, and 72 h incubation than all fucoidan fractions, and showed a
lower IC50 value than A-549 at 48 and 72 h incubation (Table 2).
Both WiDr and LoVo cells are derived from the same tissue region
(colon adenocarcinoma) yet the supplementation of both these
cells with fucoidan resulted in dissimilar decreases in cell growth
capacity (Figure 3). Incubation of WiDr and LoVo cell lines with
fucoidan both resulted in dose-dependent decreases in cell growth
capacity, with the greatest decreases observed in WiDr cells. It was
suggested that the amount of suppression in cell lines of different
fucoidans were peculiar and its effects on different kind of cancer
cells was different (49). One factor which we believe may have been
associated with the differences in inhibiting potential of fucoidan
on LoVo and WiDr cells could be the type of grade of the can-
cer cells, LoVo cells being an advanced bowel cancer type whereas
WiDr cells are not. Although no previous studies have indicated
this, it is possible that the grade of cell carcinoma could be a factor
in fucoidan’s inhibiting potential.
A pattern was also observed for the purified fucoidan fractions,
where a decrease in IC50 values (Table 2) was evident from frac-
tions F1 to F3, indicating an increase in cell reducing capacity for
WiDr, MCF-7, and A-549 cancer cell lines. In addition, it appears
that the lower the Mw of the purified fucoidan fraction, the higher
the cell reducing capacity. Low Mw and high uronic acid con-
tent can increase the cell reducing capacity potential of fucoidans
(31). Several studies have confirmed the same effect of having low
Mw and high uronic acid content in fucoidans on A-549 and gas-
tric carcinoma cell lines (1, 19). In addition, a significant increase
(p< 0.001) in sulfate content was encountered from fractions F1
(6.96%) to F3 (25.19%). Studies (11, 19, 50) have indicated that
sulfate groups play a major role in the inhibition of cancer cells that
may further aid in the suppression of cancer cells. The mechanism
by which low Mw-fucoidan polymers result in cytotoxicity has
yet to be ascertained. Assumptions have been made that the large
Mw-fucoidans have a better chance of having a compact spherical
conformation, while low Mw-fucoidans are more likely to exist in
a loosed and linear form (1). As anionic sulfate groups may be
hidden inside the spherical conformation of a large Mw-fucoidan
polymer, this leads to a decrease in the sulfate groups allowed to
react with the cancer cells. Therefore, in this study, the observed
increase in cell reducing capacity from F1 to F3 may be linked to
a combination of a lower Mw and increased sulfate content of the
F3 fraction.
Fucoidan from this study had similar effects to commer-
cial fucoidan against non-cancer cell lines, although commercial
fucoidan had stronger effects than all fucoidan fractions when
administered to HUVEC cells at 1 mg/mL fucoidan for 72 h. Sim-
ilar studies also reported that fucoidan from U. pinnatifida inhib-
ited cell proliferation of HUVEC cultures which in turn may have
potential in the prevention of angiogenesis-related diseases (51,
52). From observing Figure 3, commercial fucoidan appeared to
have a stronger cell reducing capacity rate than all fucoidan frac-
tions toward HEK-293 and HDFb cells which showed as high as
84.3 and 90.2% inhibition activity at 1 mg/mL dosage level, respec-
tively. Conversely, F3 was the less potent at 24 h incubation for all
three normal cell lines, most likely due to its low Mw of only
27 kDa.
In conclusion, crude fucoidan isolated from New Zealand U.
pinnatifida was a sulfated-xylogalactofucan. It was made up of
predominantly fucose, galactose, xylose, and sulfate, which exist
along with mannose, glucose, uronic acid, and protein as minor
constituents. The results from this study showed that sporophyll-
derived fucoidan from New Zealand U. pinnatifida had cell reduc-
ing capacity effects against MCF-7, A-549, and WiDr cells that was
comparable with commercial fucoidan from F. vesiculosis. The Mw
and degree of sulfation appeared to be related to the cytotoxicity of
purified fucoidan fractions. Fucoidan content is high in the sporo-
phyll of New Zealand U. pinnatifida which is normally regarded
as waste and would therefore be beneficial to derive fucoidan from
the sporophyll of this alga. Since fucoidan has the potential to
reducing cancer cell growth, the sporophyll of New Zealand U.
pinnatifida can be a good resource for manufacturing health prod-
ucts or produce food for health. The results have also shown that
extracted fucoidan exerts cell reducing capacity effects in a variety
of cancer cells. Even though it has toxicity at high concentration,
it exhibits anti-proliferation effect in cancer cells at concentration
lower than the normal cell toxic level. We believe it is possible to
be used to combine with other chemotherapeutic agents to treat
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cancer. Therefore, further studies on fucoidan extracted from New
Zealand U. pinnatifida are warranted, possibly in animal or clinical
trials.
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